-+ 0.00%
-+ 0.00%
-+ 0.00%

Aura Biosciences Q2 FY26 net loss widens to $45.64 million; R&D expense rises to $30.75 million

PUBT·08/11/2026 11:05:05
Listen to the news
Aura Biosciences Q2 FY26 net loss widens to $45.64 million; R&D expense rises to $30.75 million
  • Aura Biosciences posted a wider Q2 net loss of USD 45.6 million, with loss per share at USD 0.48.
  • R&D expense climbed 34.35% to USD 30.75 million, driven by CoMpass Phase 3 clinical and CRO costs plus bel-sar manufacturing.
  • G&A expense more than doubled to USD 17.32 million, on higher stock-based compensation tied to executive transitions plus higher professional fees.
  • Cash, cash equivalents, marketable securities totaled USD 323.8 million at June 30, extending projected cash runway into 1H 2029.
  • Phase 3 CoMpass trial fully enrolled with 108 patients; topline data from the 15-month primary endpoint remains on track for 2H 2027.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Aura Biosciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608110700PRIMZONEFULLFEED9807525) on August 11, 2026, and is solely responsible for the information contained therein.